Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Scott M. Wilhelm
Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
Receptor Tyrosine Kinase (RTK); VEGF-A
Science-Business eXchange
Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
Journal of Clinical Pharmacology
Pharmacology
Viral Oncolysis That Targets Raf-1 Signaling Control of Nuclear Transport
Journal of Virology
Insect Science
Immunology
Microbiology
Virology
Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling
Clinical Cancer Research
Cancer Research
Oncology
Sorafenib, a Dual Raf Kinase/Vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-Myeloma Activity and Synergizes With Common Anti-Myeloma Drugs
Oncogene
Cancer Research
Genetics
Molecular Biology
Lymphangioleiomyomatosis--Presence of Receptor Tyrosine Kinases and the Angiogenesis Factor VEGF-A as Potential Therapeutic Targets
Thorax
Pulmonary
Respiratory Medicine
Impact of Adding the Multikinase Inhibitor Sorafenib to Endocrine Therapy in Metastatic Estrogen Receptor-Positive Breast Cancer
Future Oncology
Medicine
Cancer Research
Oncology
Downregulation of Sef, an Inhibitor of Receptor Tyrosine Kinase Signaling, Is Common to a Variety of Human Carcinomas
Oncogene
Cancer Research
Genetics
Molecular Biology
Tyrosine Kinase Inhibitor and Target Therapy
